Glycan-based Drug Discovery and Development II

发布者:吕晓燕发布时间:2018-07-06浏览次数:18


In the morning of June 22, Prof. Hui Zhang and Prof. Peng Wu chaired the session of "Glycan-based Drug Discovery and Development II" at the Triumphant Hall of the Seaview Garden Hotel. In the session, Prof. Xinshan Ye, Prof. Guangli Yu and Prof. Kan Ding made academic presentations. The overview of this session is as follows:

Prof. Xinshan Ye

Prof. Xinshan Ye (Peking University, China) introduced carbohydrate-based anti-cancer vaccines. They designed and synthesized some structurally-modified carbohydrate antigens and conjugated antigens to protein carrier for vaccination. They showed that some suitable modifications on carbohydrate antigens can significantly increase the IgG titers and improve the ratios of IgG/IgM, and the antisera can recognize the tumor cells expressing the native carbohydrate antigen. They investigated the antitumor ability of the vaccines in colon cancer model and explored the mechanism of tumor immunotherapy of the vaccines.


Prof. Guangli Yu

Prof. Guangli Yu (Ocean University of China, China) made an introduction of the research and development of marine glycodrugs. The glycodrug refers to the carbohydrate-containing drug. Marine organisms are good resource of bioactive carbohydrates. Their group has already set up a marine poly-/oligosaccharides preparation and structural sequence analysis platform and constructed a Marine Carbohydrate Database. By using glycochip and intestinal microbiota screening methods, they found lot of interesting marine bioactive carbohydrates.


Prof. Kan Ding

Prof. Kan Ding (Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China) introduced natural glycan-based drug development. They found that some  glycans from seaweed, plant or mushroom might bind to VEGFR2/VEGF/Galectin-3, BMP4, EGF, Galectin-3/EGFR/BMPR/Integrin, BMP2/BMPR, respectively to either block angiogenesis or inhibit tumor cells growth in vitro or in vivo. They also found some glycans may interact with Aβ42 to inhibit Aβ42 production and impede Aβ42 aggregation, suggesting that natural glycans could be promising resource to be developed as potential new drug candidates for the complex diseases treatment.